Abstract:Background: Accurate interpretation of BRCA1/2 variants is critical for risk assessment, enhanced cancer surveillance, prevention strategies, and precise clinical treatment of breast cancer. However, current worldwide standards depend primarily on sequencing information from Caucasian populations.Methods: Panel-based sequencing served to detect BRCA1/2 variants in a Chinese multicenter cohort of 21,216 breast cancer patients (BCs) and 6,434 healthy controls (HCs).Findings: 1,245 pathogenic variants of BRCA1/2, 262 of which were novel (21.04%), and 2,517 variants of uncertain significance (VUS) were identified. Unlike in the Caucasian population, BRCA2 variants were more frequent than BRCA1 variants (56.34% versus 43.66%). The 48 most common variants accounted for 39.86% of all pathogenic variants, and were not reported as common variants in Caucasians. Furthermore, we unambiguously reclassified VUS in 508 subjects, lowering the VUS ratio from 9.05% to 7.21%. Pathogenic BRCA1/2 variants correlated with younger onset age, higher frequencies of bilateral and triple-negative BC, invasive carcinomas, high histological grades, and family history of BC and other cancers.Interpretation: Strong ethnicity-specific occurrences of pathogenic BRCA1/2 variants were identified in the Chinese population. Hence, the findings provide rationale and sequencing information for the implementation of BRCA1/2 variants tailored to the Chinese population into clinical risk assessment.Funding Statement: National Natural Science Foundation of China 81772802, Shanghai science and technology innovation action plan of China 17JC1404400 and 16DZ19102, Special Funds for Technological Innovation of Shanghai Jiao Tong University YG2016MS22, Chinese Academy of Science XDA12020223 (W.H.X), Natural Science Foundation of Zhejiang Province LZ16H160002 (C.Y.D), Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents (C.Y.D).Declaration of Interests: Authors declare no potential conflicts of interest.Ethics Approval Statement: The study was approved by the Ethics Committee of all the hospitals involved and was performed according to the Declaration of Helsinki Principles. Written consent to notify blood samples for future research was obtained for each patient under the Institutional Review Board (IRB)-approved protocol.

The frequency and pathogenicity of BRCA1 and BRCA2 variants in the general Japanese population

Development of a novel prediction model for carriage of BRCA1/2 pathogenic variant in Japanese patients with breast cancer based on Japanese organization of hereditary breast and ovarian cancer registry data

Prevalence and Reclassification of BRCA1 and BRCA2 Variants in a Large, Unselected Chinese Han Breast Cancer Cohort

Population-based Screening for Hereditary Colorectal Cancer Variants in Japan

Identification of <i>BRCA1</i>:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants

Significance of the Multi-gene Panel myRisk in Japan

High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands

Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis

Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients

BRCA1 and BRCA2 Variation in Taiwanese General Population and the Cancer Cohort

BRCA1 Germline Mutations in Chinese Patients with Hereditary Breast and Ovarian Cancer.

Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes

Mutational landscape of Japanese patients with oral squamous cell carcinoma from comprehensive genomic profiling tests

Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil

Familial and hereditary pancreatic cancer in Japan

Mutation spectra of the BRCA1/2 genes in human breast and ovarian cancer and germline

Human genetic variation database, a reference database of genetic variations in the Japanese population

Retrospective analysis of non-BRCA gene pathogenicity variation in Chinese patients with ovarian cancer.

Hereditary Gastric Cancer Is Linked With Hereditary Breast and Ovarian Cancer

Genomic landscape of comprehensive genomic profiling in patients with malignant solid tumors in Japan